Media Coverage


Media Coverage

JAMMU, India—Sami Labs, sister company of Sabinsa, has entered into a tripartite agreement with the Indian Institute of Integrative Medicine (IIIM) and the Indian Council of Medical Research (ICMR) that allowed Sami and Sabinsa to acquire two Indian ( patents pertaining to pterocarpus marsupium, an existing ingredient in the Sabinsa global product portfolio.

The agreement was signed at IIIM by Ram A. Vishwakarma, Ph.D., Director, IIIM; Sadhana Srivastava, Ph.D., Scientist, ICMR; and Muhammed Majeed, Ph.D., Founder and Managing Director, Sami Labs Limited. R. K. Raina, Ph.D., Consultant to IIIM; Sarang Bani, Ph.D., Director, Biological Science at Sami Labs; and Abdul Rahim, Head of PME, were also present.

IIIM, based in Jammu, is one of the oldest institutions of the Council of Scientioec and Industrial Research (CSIR), and was established in 1957. It is dedicated to advanced research on the isolation and standardization of drugs from natural products useful against various diseases. ICMR has led research on the isolation of novel compounds from pterocarpus marsupium for blood sugar ( management and two novel compunds were isolated, which showed signioecant activity in that area.

The two Indian patents ( for Sami/Sabinsa ( are:

  • “A process for isolation of novel compound 2,6-dihydroxy-2-(P-hydroxybenzyl)-3(2H)-benzofuranone-7-C-ß-D-glucopyranoside from pterocarpus marsupium" under Patent No. 192163
  • “A process for extraction of antidiabetic formulation mainly containing flavonoid glycosides" under Patent No. 194292